• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 7

Episode 6 - Treatment Response Rates in Step Therapy

Video

During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss the challenges clinicians face when developing a drug-sequencing plan for patients with castration-resistant prostate cancer.

Dr Quinn explains that because not all patients respond to the same types of therapy, there is a need for data that reveals the appropriateness of agents suggested in step therapy plans.

To address this challenge, he suggests that new clinical trials test comparative effectiveness, which he believes can help determine response rates for specific groups of patients.

Dr Kolodziej argues that receiving this data will take too long, and suggests receiving aid from professional services that can structure current data into an actionable format. He explains that this may help provide quick answers about step therapy and can improve the clinician’s decision-making process.


Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Pat Van Burkleo
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Pat Van Burkleo
dr robert sidbury
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Ben Jones, McKesson/Us Oncology
Will Shapiro, vice president of data science, Flatiron Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.